Document and Entity Information
Document and Entity Information | Mar. 24, 2021 |
Cover [Abstract] | |
Security Exchange Name | NASDAQ |
Amendment Flag | true |
Entity Central Index Key | 0001711279 |
Document Type | 8-K/A |
Document Period End Date | Mar. 24, 2021 |
Entity Registrant Name | KRYSTAL BIOTECH, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38210 |
Entity Tax Identification Number | 82-1080209 |
Entity Address, Address Line One | 2100 Wharton Street |
Entity Address, Address Line Two | Suite 701 |
Entity Address, City or Town | Pittsburgh |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 15203 |
City Area Code | (412) |
Local Phone Number | 586-5830 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock |
Trading Symbol | KRYS |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
Amendment Description | On March 24, 2021, Krystal Biotech, Inc. (the “Company”) filed a Current Report on Form 8-K reporting that it had issued a press release announcing the launch of Jeune, Inc. (which has subsequently been renamed Jeune Aesthetics, Inc) (“Jeune”), a gene-based aesthetics company, and the initial safety data from the ongoing Phase 1 trial of KB301 for aesthetic indications. Jeune continues to manage the development of a portfolio of aesthetic indication candidates based on the Company’s proprietary technology platform. The formal license between the Company and Jeune referred to in the press release has not been finalized as Jeune remains a wholly-owned subsidiary of the Company. The Company furnished the press release on a Current Report on Form 8-K dated March 24, 2021 under Item 7.01. The Company is filing this amendment to such Current Report solely to correct the disclosure within the press release attached to such Current Report and incorporated therein. |